Effect of methyl donor supplementation in treatment of overweight and obesity

Processing and production of a methyl donor supplement (choline,folic acid, cobalamine, pyrodoxine and riboflavin) and the assessment of its effects on the anthropometric measurements, glycemic indices, lipid profile, appetite regulating hormones and the level of gene expression of leptin in overweight and obese subjects

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180528039881N1

Enrollment

Registered

2018-12-18

Start date

2018-09-23

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and obesity. Overweight and obesity

Interventions

Intervention 1: Intervention group: Overweight or obese subject received methyl donor supplement( contents : vitamin B2: 3mg,vitamin B6: 5mg, vitamin B12: 7.5 µg, choline: 600 mg,vitaminB 9: 1000µg),

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: People with overweight and obesity (BMI=25) whose serum homocysteine levels are higher than normal (15 mcmol / L), or at the highest levels of homocysteine serum levels The age range between 20-60 years Residence in Shiraz Ability to understand the goals of study and provide informed written consent The desire to participate in the study

Exclusion criteria

Exclusion criteria: History of any severe systemic disease, endocrine or metabolic disorders Using any type of lipid and glucose lowering drug Taking any type of food supplement and herbal remedies in the last 6 months History of any allergy, intolerance, or adverse drug reaction to the supplements studied Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Homocysteine. Timepoint: The beginning and the end of the study. Method of measurement: serum homocysteine level.	—

Secondary

Measure	Time frame
Anthropometric measurements. Timepoint: The beginning, the forth week and the end of the study. Method of measurement: stadiometer, mechanical scales and body analyzer.;Blood suger. Timepoint: The beginning and the end of the study. Method of measurement: serum blood suger.;Lipid profile. Timepoint: The beginning and the end of the study. Method of measurement: Serum Lipid Profile.;The beginning and the end of the study. Timepoint: ????????? ????? ????? ?????. Method of measurement: Serum leptin and gherelin.;Leptin gene expresion. Timepoint: The beginning and the end of the study. Method of measurement: Real time- PCR mehthod.	—

Measure

Time frame

Anthropometric measurements. Timepoint: The beginning, the forth week and the end of the study. Method of measurement: stadiometer, mechanical scales and body analyzer.;Blood suger. Timepoint: The beginning and the end of the study. Method of measurement: serum blood suger.;Lipid profile. Timepoint: The beginning and the end of the study. Method of measurement: Serum Lipid Profile.;The beginning and the end of the study. Timepoint: ????????? ????? ????? ?????. Method of measurement: Serum leptin and gherelin.;Leptin gene expresion. Timepoint: The beginning and the end of the study. Method of measurement: Real time- PCR mehthod.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactmaryam Ranjbar Zahedani

Shiraz University of Medical Sciences

ranjbarmaryam29@yahoo.com+98 717251005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026